Phase II Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Sunitinib (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 02 Jun 2017 Results (n=12) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 21 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 21 Jun 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.